Get the Weekly Intelligence Brief — top committee picks every Sunday.

ACAD vs TGTX

ACADIA Pharmaceuticals Inc. vs TG Therapeutics, Inc. — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
TGTX
TG Therapeutics, Inc.
60
Watch
MetricACADTGTX
AI Score 69 60
Price $29.41 $49.86
P/E Ratio 13.07× 16.39×
ROE 31.9% 69.0%
Revenue Growth YoY
Gross Margin 91.1% 82.4%
Debt / Equity 0.06× 1.25×
Dividend Yield 0.0% 0.0%
RSI (14) 78.4 42.0
Beta 0.845 1.666
Expected Upside

AI Committee View

Current Innellis committee reasoning for ACAD versus TGTX.
ACAD leads by 9 points.

ACAD scores 69/100 (Buy) versus TGTX at 60/100 (Watch).

ACAD Committee View
83% agreement
6 analysts

The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.

Bull Case
  • P/E of 13.2 is inexpensive for the broad market — Value
  • ROE of 32.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
  • RSI at 78 is in overbought territory — Technical
  • Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
  • Bollinger bandwidth of 24.3% signals elevated volatility — Risk
TGTX Committee View
50% agreement
6 analysts

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 76.1% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 22.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • ROE of 72.3% shows genuine earnings power backing the valuation — Value
  • Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
  • EPS growing 633.7% YoY — Growth
Bear Case
  • Price-to-book of 21.1x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 22.5% signals elevated volatility — Risk
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ACAD Full Analysis TGTX Full Analysis